PlushCare
Telehealth Provider — FDA safety data from public records
On This Page
Accolade-owned telehealth platform offering GLP-1 prescribing alongside primary care, mental health, and urgent virtual-care services.
Website: plushcare.com
Data last verified: 2026-04-25
Company Snapshot
Entity Type
Telehealth Provider
FDA Registration
Not shown
Warning Letters
0
Recalls
0
States Licensed
50
Compounding Status
unknown
What This Company Profile Actually Tells You
PlushCare is best understood as a telehealth front end rather than a manufacturer. Patients usually encounter the brand through online intake, clinician review, subscription billing, fulfillment coordination, and follow-up support, while the medication supply chain sits behind the scenes with partner pharmacies or outsourcing facilities.
PlushCare reports coverage across 50 states, which suggests a relatively broad operating footprint rather than a niche single-state presence. For SEO and user trust, that means the important question is not just "is PlushCare legitimate" but "who is prescribing, who is compounding or dispensing, and what claims is the company making about those medications?"
Telehealth companies can scale quickly because marketing, acquisition, and patient communications are centralized. The tradeoff is that a polished consumer brand can sometimes hide weak transparency around pharmacy sourcing, state licensure details, refill logic, escalation paths, and how the company handles adverse events or billing disputes.
PlushCare Background
Market Position
PlushCare sits in the larger consumer-telehealth tier and tends to compete on accessibility and mainstream brand comfort rather than on extreme specialization or lowest-cost compounded medication access.
Business Model
The company extends a broad virtual primary-care model into weight loss. That can improve convenience for users already comfortable with general telehealth, but it also means patients should confirm how specialized the GLP-1 pathway really is.
Pharmacy And Supply Notes
PlushCare itself is not the compounding or manufacturing site, so readers should focus on who prescribes, who dispenses, and how clearly the medication source is explained.
Consumer Risk Notes
Patients should not assume that strong general telehealth operations automatically translate into the best obesity-care experience. The useful diligence questions are around medication access, follow-up cadence, and support quality.
Key Facts
PlushCare is a broad telehealth platform with a GLP-1 offering, not a weight-loss-only specialist.
Its value proposition is convenience and mainstream telehealth familiarity.
Patients should verify medication sourcing and the actual depth of weight-loss follow-up.
Risk Summary
No FDA warning letters are currently shown in this profile.
No recall events are currently shown in the FDA enforcement data surfaced here.
No direct FDA establishment registration record is displayed on this page.
The page shows an operating footprint of 50 states.
Regulatory And Compliance Analysis
Registration Context
PlushCare does not appear in this profile as a directly FDA-registered drug establishment. That is common for telehealth platforms because they usually operate as prescriber and logistics layers while medications are sourced through partner pharmacies or outsourcing facilities.
Warning Letter Readout
We did not find FDA warning letters for PlushCare in this profile. That is better than the alternative, but it is not a blanket endorsement. A clean warning-letter record only tells you that this page is not currently surfacing a published FDA warning letter tied to the entity.
Recall Readout
No recall events are shown for PlushCare here. For consumers, that lowers one category of concern, but it still does not replace verification of sourcing, labeling, temperature handling, and pharmacy quality controls.
Adverse Event Context
This profile does not currently show a meaningful adverse-event dataset for PlushCare. In practice, that usually means readers should lean more heavily on registration, recalls, warning letters, and pharmacy-partner transparency when evaluating risk.
FDA Registration
No direct FDA establishment registration record is shown in this profile for PlushCare. For telehealth companies, that is often expected because the brand may coordinate care while external pharmacies or outsourcing facilities handle compounding or dispensing. Readers should verify the underlying pharmacy partner rather than relying on the consumer brand alone.
FDA Warning Letters (0)
No FDA warning letters are currently shown for PlushCare in this profile. That is helpful context, but users should still verify current marketing claims, pharmacy sourcing, and how the company describes compounded medications.
Recall History (0)
No recalls are currently displayed for PlushCare in the openFDA enforcement data surfaced on this page. That lowers one obvious risk signal, but it should not be treated as proof that all products, batches, or fulfillment practices are problem-free.
Source: openFDA Drug Enforcement API
Adverse Event Reports
This profile does not currently show a meaningful adverse-event summary for PlushCare. When that dataset is absent, readers should lean more on the documented public record around registration, recalls, warning letters, and pharmacy-partner transparency.
Source: FDA Adverse Event Reporting System (FAERS). Adverse event reports do not establish causation.
Questions Patients Should Ask Before Using PlushCare
Which pharmacy or outsourcing facility is actually filling PlushCare prescriptions, and can you name it before checkout?
What does PlushCare tell patients about compounded versus FDA-approved products, and does that language avoid implying equivalence or approval where it does not exist?
How does PlushCare handle dose escalations, refill delays, refunds, cancellations, and temperature-sensitive shipping problems?
If a patient has a side effect or receives a product-quality concern, what is the human escalation path and how quickly does PlushCare respond?
Can PlushCare provide lot-level documentation, pharmacy details, and a clear explanation of what safety checks happen before medication is dispensed?
Similar Companies
These related profiles are useful for searchers comparing PlushCare against adjacent providers or pharmacies. Reading similar pages side by side usually reveals whether a concern is unique to one company or common across this category.
How To Use This Profile
This profile organizes public-source safety signals for PlushCare, including FDA registration status, warning letters, recalls, and any adverse event summary data available in the dataset.
A company can appear relatively clean here and still deserve more diligence, because absence of a warning letter or recall is not the same as proof of quality.
For telehealth provider pages especially, readers should distinguish between the consumer-facing brand and the pharmacy or facility that actually handles medication production or dispensing.
Looking for a Verified GLP-1 Provider?
FormBlends partners with licensed 503A compounding pharmacies. Every compound is third-party tested with certificates of analysis.
Learn MoreDisclaimer: This page aggregates publicly available data from the FDA, state pharmacy boards, and other government sources. It is provided for informational purposes only and does not constitute medical or legal advice. FDA registration does not imply FDA approval or endorsement. The absence of warning letters or recalls does not guarantee safety or quality. Always consult your healthcare provider before making decisions about medications. Data may not reflect the most current status. Last updated: 2026-04-25.
Safety Guides
503A vs 503B pharmacies
Understanding the FDA oversight difference.
How to read a Certificate of Analysis
What every CoA should include and red flags to watch for.
What FDA registration actually means
Registration vs approval: the distinction most people miss.
Choosing a compounding pharmacy
What to verify before you fill your first prescription.
GLP-1 Safety Alerts
Get notified when the FDA issues warning letters, recalls, or regulatory updates affecting GLP-1 medications and compounding pharmacies.
Free. No spam. Unsubscribe anytime.
Frequently Asked Questions
Is PlushCare FDA registered?
We do not currently have FDA registration data for PlushCare. This may mean the company operates under a different entity name or is regulated at the state level.
Has PlushCare received any FDA warning letters?
We have not found any FDA warning letters issued to PlushCare in our records. This page is updated regularly as new FDA data becomes available.
Does PlushCare have any recalls?
We have not found any recalls associated with PlushCare in the openFDA enforcement database.
Is PlushCare a telehealth company or a pharmacy?
PlushCare is categorized in this profile as a telehealth provider. That distinction matters because a telehealth brand, a 503A pharmacy, and a 503B outsourcing facility operate under different regulatory expectations.
Does a clean profile mean PlushCare is definitely safe?
No. A clean profile means we are not currently surfacing certain FDA signals like warning letters or recalls for PlushCare. It does not guarantee product quality, customer-service quality, or future regulatory compliance.
What should patients verify before using PlushCare?
Patients should verify who is prescribing, which pharmacy or outsourcing facility is actually fulfilling the medication, what the company says about compounded versus FDA-approved products, and how billing, cancellations, and side-effect escalation are handled.